Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2016 17:35 ET | Source: ApeX Therapeutics, Inc.

ApeX Therapeutics Files IND to Initiate Phase 1 Study to Evaluate the Tolerability and Anti-Tumor Effects of APX3330

INDIANAPOLIS, IN--(Marketwired - June 20, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced the filing of an Investigation New...
May 12, 2016 16:00 ET | Source: Apex Therapeutics, Inc.

ApeX Therapeutics and Researchers at Indiana University to Present Phase 1 Clinical Plan for APX3330 and Novel Approach to Addressing Therapeutic Resistance at AACR Pancreatic Cancer Meeting

INDIANAPOLIS, IN--(Marketwired - May 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, in collaboration with researchers at Indiana...
April 12, 2016 08:00 ET | Source: Apex Therapeutics, Inc.

ApeX Therapeutics to Present Ability of APX3330 to Target Multiple Oncogenic Transcription Factors in Pancreatic Cancer as Single Agent or Combination Therapy at AACR Annual Meeting

INDIANAPOLIS, IN--(Marketwired - April 12, 2016) - ApeX Therapeutics, a biotechnology company focused on developing novel compounds to treat cancer, today announced three poster presentations...